[Prostate cancer treated with androgen deprivation therapy: Care and monitoring in daily practice].

[1]  L. Walker,et al.  Patients and partners lack knowledge of androgen deprivation therapy side effects. , 2013, Urologic oncology.

[2]  R. Hoermann,et al.  Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non‐metastatic prostate cancer: implementation of standardized management guidelines , 2013, Andrology.

[3]  T. Cheetham,et al.  Osteoporosis management program decreases incidence of hip fracture in patients with prostate cancer receiving androgen deprivation therapy. , 2013, Urology.

[4]  I. Tannock,et al.  Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D , 2013, Osteoporosis International.

[5]  É. Lartigau,et al.  Suppression androgénique dans le cancer de la prostate et risque ostéoporotique , 2012 .

[6]  C. E. Lee,et al.  Efficacy of walking exercise in promoting cognitive-psychosocial functions in men with prostate cancer receiving androgen deprivation therapy , 2012, BMC Cancer.

[7]  M. Rouprêt,et al.  [The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the 'ELIRE' observational study]. , 2011, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[8]  B. Tombal,et al.  Cancer Management and Research Dovepress Cardiovascular Risk during Hormonal Treatment in Patients with Prostate Cancer , 2022 .

[9]  M. Peyromaure,et al.  Recommandations en Onco-Urologie 2010 : Cancer de la prostate , 2010 .

[10]  A. D'Amico,et al.  Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. , 2010, Circulation.

[11]  M. Piérart,et al.  Duration of androgen suppression in the treatment of prostate cancer. , 2009, The New England journal of medicine.

[12]  Xianglin L. Du,et al.  Review of major adverse effects of androgen‐deprivation therapy in men with prostate cancer , 2009, Cancer.

[13]  M. Cherrier,et al.  Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non‐metastatic prostate cancer , 2009, Psycho-oncology.

[14]  A. D'Amico,et al.  Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. , 2007, Journal of the National Cancer Institute.

[15]  N. Keating,et al.  Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Collette,et al.  Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Maggie Watson,et al.  Prostate cancer patients' support and psychological care needs: Survey from a non‐surgical oncology clinic , 2003, Psycho-oncology.

[18]  Aurélien Belot,et al.  Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2005 , 2008 .